Gossamer Bio, Inc. (GOSS)

Market Cap	96.15M -61.8%
Revenue (ttm)	44.05M -58.2%
Net Income	-156.16M
EPS	-0.69
Shares Out	231.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	71,287,175
Open	0.3881
Previous Close	0.4233
Day's Range	0.3560 - 0.4445
52-Week Range	0.3315 - 3.8700
Beta	1.95
Analysts	Buy
Price Target	5.90 (+1,320.32%)
Earnings Date	Mar 12, 2026

About GOSS

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The compa...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 8, 2019
• Employees: 145
• Stock Exchange: NASDAQ
• Ticker Symbol: GOSS
• Website: https://www.gossamerbio.com

Analyst Summary

According to 8 analysts, the average rating for GOSS stock is "Buy." The 12-month stock price target is $5.9, which is an increase of 1,320.32% from the latest price.

Price Target

$5.9

(1,320.32% upside)

Analyst Consensus: Buy